BAUDETTE, Minn., April 2, 2020 /PRNewswire/ -- ANI
Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the
launch of Omega-3-Acid Ethyl Esters Capsules USP, 1 gram. The
current annual U.S. market for this product is approximately
$110 million, according to IQVIA/IMS
Health.
Arthur S. Przybyl, ANI's
President and CEO stated, "This is our fifth generic product launch
in 2020. The product was developed by Sofgen Pharmaceuticals as
part of our development, manufacturing and commercialization
partnership. The launch expands our commercial generic portfolio to
49 drugs."
About Omega-3-Acid Ethyl Esters Capsules USP
Omega-3-Acid Ethyl Esters Capsules are indicated as an adjunct
to diet to reduce triglyceride (TG) levels in adult patients with
severe (greater than or equal to 500mg per dL) hypertriglyceridemia
(HGT). For more information, including the complete list of
indications and usages, please see the Full Prescribing
Information.
About ANI
ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated
specialty pharmaceutical company developing, manufacturing, and
marketing branded and generic prescription pharmaceuticals. The
Company's targeted areas of product development currently include
narcotics, oncolytics (anti-cancers), hormones and steroids, and
complex formulations involving extended release and combination
products. For more information, please visit our website
www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with
information that is not historical, these are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, statements about price increases, the Company's future
operations, products financial position, operating results and
prospects , the Company's pipeline or potential markets therefor,
and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"will," "expects," "plans," "potential," "future," "believes,"
"intends," "continue," other words of similar meaning, derivations
of such words and the use of future dates.
Uncertainties and risks may cause the Company's actual results to
be materially different than those expressed in or implied by such
forward-looking statements. Uncertainties and risks include, but
are not limited to, the risk that the Company may face with respect
to importing raw materials; increased competition; acquisitions;
contract manufacturing arrangements; delays or failure in obtaining
product approval from the U.S. Food and Drug Administration;
general business and economic conditions; market trends; products
development; regulatory and other approvals and marketing.
More detailed information on these and additional factors that
could affect the Company's actual results are described in the
Company's filings with the Securities and Exchange Commission,
including its most recent annual report on Form 10-K and quarterly
reports on Form 10-Q, as well as its proxy statement. All
forward-looking statements in this news release speak only as of
the date of this news release and are based on the Company's
current beliefs, assumptions, and expectations. The Company
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information about ANI, please contact:
Investor Relations
IR@anipharmaceuticals.com
View original
content:http://www.prnewswire.com/news-releases/ani-pharmaceuticals-announces-launch-of-omega-3-acid-ethyl-esters-capsules-usp-301033781.html
SOURCE ANI Pharmaceuticals, Inc.